U.S. Dollar (DXY) Rolling Over Large-cap indexes (S&P 500, Nasdaq 100, and DJI) remain bullish, all hitting new all-time highs last week while continuing to find short-term support at their respective 20-day MAs. Mid-caps (S&P 400, Russell Mid-Cap) are starting another leg higher following breakouts from 2-month consolidations. Small-caps (S&P 600, Russell 2000) are likely to follow in the footsteps of large- and mid-caps, and are likely to break out from their 2.5-month consolidations/high bas...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Upgrading Staples and Health Care to Market Weight As the saying goes, "sector rotation is the lifeblood of a bull market." That appears to be exactly what is going on as we kick off 2024. Leadership areas that have significantly outperformed since the October 2023 lows are starting to pull back rather hard -- and on above average volume. This includes areas such as Technology (XLK), semiconductors (SMH), software (IGV), and the ARKK, IPO, and BITQ ETFs. This tells us a pause/pullback is likely...
Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren...
The general evaluation of VIATRIS (US), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 2 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date April 1, 2022, the closing price was USD 10.82...
The market is pricing in a reckoning for the memory chip supply market, to which ICHR is a key supplier. Expectations are for the company's earning power to fade to historically low levels, even as the memory market is in a secular growth cycle. The market expects Ichor, which has seen UAFRS-based ROA (Uniform ROA or ROA′) remain above 20% in each of the last seven years, to fade to an all-time low. This seems to be ignoring both Ichor's dominant position in its sub-industry and the memory mar...
Viatris Inc. (VTRS:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with a 22.0x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, and management may have concerns about progress on their pipeline, ongoing pandemic-induced headwinds, and meeting their financial targets. Moreover, management may lack confidence in their ability to maintain strong financial results, deliver their financial targets, and further pay d...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.